All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Shares of Geron Corp. hit a 52-week low Monday as investors found an interim update on the phase II program of telomerase inhibitor imetelstat less than encouraging.
